Current status of therapeutic monoclonal antibodies against SARS-CoV-2

被引：70
|
作者：
Kumar, Sanjeev [1 ]
Chandele, Anmol [1 ]
Sharma, Amit [2 ,3 ]
机构：
[1] Int Ctr Genet Engn & Biotechnol, ICGEB Emory Vaccine Ctr Program, New Delhi, India
[2] Int Ctr Genet Engn & Biotechnol, Struct Parasitol Grp, New Delhi, India
[3] Natl Inst Malaria Res, New Delhi, India
来源：
PLOS PATHOGENS | 2021年 / 17卷 / 09期
基金：
英国惠康基金;
关键词：
D O I：
10.1371/journal.ppat.1009885
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
AMP Exception</p>
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Current status of therapeutic monoclonal antibodies against SARS-CoV-2 (vol 17, e1009885, 2021)
    Kumar, Sanjeev
    Chandele, Anmol
    Sharma, Amit
    PLOS PATHOGENS, 2022, 18 (11)
  • [2] Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
    Quiros-Roldan, Eugenia
    Amadasi, Silvia
    Zanella, Isabella
    Degli Antoni, Melania
    Storti, Samuele
    Tiecco, Giorgio
    Castelli, Francesco
    PHARMACEUTICALS, 2021, 14 (12)
  • [3] Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
    Xie, Jiajia
    Ding, Chengchao
    He, Jun
    Zhang, Yuqing
    Ni, Shuangshuang
    Zhang, Xiangyu
    Chen, Qingqing
    Wang, Jing
    Huang, Lina
    He, Hongliang
    Li, Wenting
    Ma, Huan
    Jin, Tengchuan
    Zhang, Siping
    Gao, Yong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [4] Therapeutic antibodies and alternative formats against SARS-CoV-2
    Winiger, Rahel R.
    Perez, Laurent
    ANTIVIRAL RESEARCH, 2024, 223
  • [5] Monoclonal neutralizing antibodies against SARS-COV-2 S protein
    Cheng, Lin-Dong
    Li, Ping
    Lin, Yan-Chen
    Hu, Hui-Xiu
    Zhang, Ying
    Li, Hou-Feng
    Huang, Jing
    Tan, Li
    Ma, Ning
    Xia, Deng-Yun
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (02): : 681 - 689
  • [6] Current status of therapeutic approaches and vaccines for SARS-CoV-2
    Wahid, Braira
    Amir, Anam
    Ameen, Ayesha
    Idrees, Muhammad
    FUTURE MICROBIOLOGY, 2021, 16 (17) : 1319 - 1326
  • [7] Current Status and Perspectives of Therapeutic Antibodies Targeting the Spike Protein S2 Subunit against SARS-CoV-2
    Yamamoto, Yuichiro
    Inoue, Tetsuya
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2024, 47 (05) : 917 - 923
  • [8] Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
    Huang, Kuan-Ying A.
    Zhou, Daming
    Tan, Tiong Kit
    Chen, Charles
    Duyvesteyn, Helen M. E.
    Zhao, Yuguang
    Ginn, Helen M.
    Qin, Ling
    Rijal, Pramila
    Schimanski, Lisa
    Donat, Robert
    Harding, Adam
    Gilbert-Jaramillo, Javier
    James, William
    Tree, Julia A.
    Buttigieg, Karen
    Carroll, Miles
    Charlton, Sue
    Lien, Chia-En
    Lin, Meei-Yun
    Chen, Cheng-Pin
    Cheng, Shu-Hsing
    Chen, Xiaorui
    Lin, Tzou-Yien
    Fry, Elizabeth E.
    Ren, Jingshan
    Ma, Che
    Townsend, Alain R.
    Stuart, David, I
    THERANOSTICS, 2022, 12 (01): : 1 - 17
  • [9] Cartography of SARS-CoV-2 variants based on the susceptibility to therapeutic monoclonal antibodies
    Furuse, Yuki
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [10] Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
    Yamasoba, Daichi
    Kosugi, Yusuke
    Kimura, Izumi
    Fujita, Shigeru
    Uriu, Keiya
    Ito, Jumpei
    Sato, Kei
    LANCET INFECTIOUS DISEASES, 2022, 22 (07): : 942 - 943
12345